{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:04:40Z","timestamp":1788887080876,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:00:00Z","timestamp":1511913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ctrv.2017.11.009","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T05:47:24Z","timestamp":1512539244000},"page":"135-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs"],"prefix":"10.1016","volume":"63","author":[{"given":"Carmela","family":"Coppola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Piscopo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Arra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Maurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2017.11.009_b0005","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0010","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","article-title":"Molecularly targeted oncology therapeutics and prolongation of the QT interval","volume":"25","author":"Strevel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0002-8703(47)90421-3","article-title":"The duration of the electrical systole (Q-T) in acute rheumatic carditis in children","volume":"33","author":"Taran","year":"1947","journal-title":"Am Heart J"},{"key":"10.1016\/j.ctrv.2017.11.009_b0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1542-474X.2003.08413.x","article-title":"The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920","volume":"8","author":"Fridericia","year":"2003","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0025","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0002-9149(92)90562-D","article-title":"An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)","volume":"70","author":"Sagie","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0030","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1046\/j.1365-2125.2003.01791.x","article-title":"Variability of heart rate correction methods for the QTinterval","volume":"55","author":"Desai","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0035","unstructured":"Guidance for Industry: E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available at: <http:\/\/www.fda.gov\/downloads\/Regulatory\/Information\/Guidances\/ucm129357.pdf> [accessed May 13, 2013]."},{"key":"10.1016\/j.ctrv.2017.11.009_b0040","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v 4.0. Available at: <http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf> [accessed May 13, 2013]."},{"key":"10.1016\/j.ctrv.2017.11.009_h0045","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pcad.2010.05.005","article-title":"Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy","volume":"53","author":"Brell","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ctrv.2017.11.009_h0050","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1067\/mhj.2002.125804","article-title":"Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management","volume":"144","author":"Anderson","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.ctrv.2017.11.009_b0050","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/11587800-000000000-00000","article-title":"Assessing QT interval prolongation and its associated risks with antipsychotics","volume":"25","author":"Nielsen","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ctrv.2017.11.009_b0055","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1592\/phco.30.7.684","article-title":"Drug-induced QT-interval prolongation: considerations for clinicians","volume":"30","author":"Li","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.ctrv.2017.11.009_b0060","first-page":"246","article-title":"Onco-Cardiology. The Time Has Come","volume":"38","author":"Yeh","year":"2011","journal-title":"Tex Heart Inst J Cancer Heart"},{"key":"10.1016\/j.ctrv.2017.11.009_b0065","unstructured":"CredibleMeds QT drugs list website sponsored by Science Foundation of the University of Arizona. Available at <http:\/\/crediblemeds.org\/>."},{"key":"10.1016\/j.ctrv.2017.11.009_b0070","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.2459\/JCM.0000000000000383","article-title":"A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology","volume":"17","author":"Maurea","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.ctrv.2017.11.009_b0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.taap.2009.12.032","article-title":"The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity","volume":"244","author":"Hasinoff","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","article-title":"Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.ctrv.2017.11.009_b0085","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Ghatalia","year":"2015","journal-title":"Br J Cancer"},{"issue":"131","key":"10.1016\/j.ctrv.2017.11.009_b0090","doi-asserted-by":"crossref","first-page":"131ra50","DOI":"10.1126\/scitranslmed.3003623","volume":"4","author":"Lu","year":"2012","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.ctrv.2017.11.009_b0095","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Ghatalia","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2017.11.009_b0100","unstructured":"US FDA drug approval summary for vandetanib in medullary thyroid cancer available online at <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022405s000lbl.pdf> [accessed on April 25, 2011]."},{"key":"10.1016\/j.ctrv.2017.11.009_b0105","doi-asserted-by":"crossref","first-page":"e30353","DOI":"10.1371\/journal.pone.0030353","article-title":"Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis","volume":"7","author":"Zang","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2017.11.009_b0110","unstructured":"FDA-approved manufacturer's package insert for vandetanib available online at <http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525> [accessed on January 25, 2013]."},{"key":"10.1016\/j.ctrv.2017.11.009_b0115","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3322\/caac.20075","article-title":"Angiogenesis inhibitors: current strategies and future prospects","volume":"60","author":"Cook","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2017.11.009_b0120","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.11.009_b0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00280-012-2030-8","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors","volume":"71","author":"Heath","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.11.009_b0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.11.009_b0145","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0150","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2017.11.009_b0155","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1634\/theoncologist.2009-0235","article-title":"Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies","volume":"15","author":"Girardi","year":"2010","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.ctrv.2017.11.009_b0160","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","article-title":"Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors","volume":"18","author":"Lenihan","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2017.11.009_b0165","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/1078-0432.CCR-09-1521","article-title":"Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib","volume":"15","author":"Bello","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.11.009_b0170","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2008-0120","article-title":"Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies","volume":"13","author":"Hutson","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2017.11.009_b0175","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00280-010-1372-3","article-title":"A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer","volume":"67","author":"Tolcher","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0180","unstructured":"http:\/\/www.agenziafarmaco.gov.it."},{"key":"10.1016\/j.ctrv.2017.11.009_b0185","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1742-7843.2010.00556.x","article-title":"Electrophysiological effects of the anti-cancer drug lapatinib on cardiac repolarization","volume":"107","author":"Lee","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.ctrv.2017.11.009_b0190","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1188\/11.CJON.660-667","article-title":"Identification of side effects associated with intolerance to BCR-ABL inhibitors in patients with chronic myeloid leukemia","volume":"15","author":"Rios","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.ctrv.2017.11.009_b0195","unstructured":"Bristol-Myers Squibb Company: Sprycel (dasatinib) prescribing information. Princeton, NJ; 2006."},{"key":"10.1016\/j.ctrv.2017.11.009_b0200","unstructured":"http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=32204&CFID=11456208&CFTOKEN=1f74eda9f81e615f-6771DE68-92AA-956A3738E4B0F5A05DA7&jsessionid=ca30878 ec315457e3b38 [accessed on November 22, 2010]."},{"key":"10.1016\/j.ctrv.2017.11.009_b0205","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.11.009_b0210","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-08-1215","article-title":"Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma","volume":"15","author":"Woo","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.11.009_b0215","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","article-title":"Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.11.009_b0220","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0225","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","article-title":"Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors","volume":"12","author":"Shah","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.11.009_b0230","first-page":"269","article-title":"Panobinostat for the treatment of multiple myeloma: the evidence to date","volume":"6","author":"Bailey","year":"2015","journal-title":"J Blood Med"},{"key":"10.1016\/j.ctrv.2017.11.009_b0235","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(02)21638-4","article-title":"Notes of a case of leukocythaemia","volume":"119","author":"Doyle","year":"1882","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2017.11.009_b0240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1001\/jama.1931.02730010007002","article-title":"Arsenic as a therapeutic agent in chronic myelogenous leukemia","volume":"97","author":"Forkner","year":"1931","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2017.11.009_b0245","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/annonc\/mdj019","article-title":"Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and\/or chemotherapy","volume":"17","author":"Ghavamzadeh","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0250","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2005-08-3532","article-title":"Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity","volume":"107","author":"Mathews","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.11.009_b0255","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJM198011063031905","article-title":"Arsenic-induced atypical ventricular tachycardia","volume":"303","author":"Goldsmith","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.11.009_b0260","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1540-8159.1990.tb05066.x","article-title":"Torsade de pointes and T-U wave alternans associated with arsenic poisoning","volume":"13","author":"Little","year":"1990","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0265","first-page":"367","article-title":"Ventricular fibrillation caused by arsenic poisoning","volume":"120","author":"St Petery","year":"1970","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.ctrv.2017.11.009_b0270","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0002-8703(60)90129-0","article-title":"The electrocardiogram in acute arsenic poisoning","volume":"60","author":"Weinberg","year":"1960","journal-title":"Am Heart J"},{"key":"10.1016\/j.ctrv.2017.11.009_b0275","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","article-title":"Effect of arsenic trioxide on QT interval in patients with advanced malignancies","volume":"21","author":"Barbey","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0280","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/01.CIR.0000109484.00668.CE","article-title":"Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents","volume":"109","author":"Drolet","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ctrv.2017.11.009_b0285","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0290","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.11.009_b0295","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2017.11.009_b0300","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1186\/s40064-016-3674-3","article-title":"Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments","volume":"5","author":"Wei","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.ctrv.2017.11.009_b0305","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/cncr.28040","article-title":"Heart rate decrease during crizotinib treatment and potential correlation to clinical response","volume":"119","author":"Ou","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2017.11.009_b0310","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2125.2010.03660.x","article-title":"Drug- and non-drug-associated QT interval prolongation","volume":"70","author":"van Noord","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ctrv.2017.11.009_b0315","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00280-016-2980-3","article-title":"Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab","volume":"77","author":"Agrawal","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.ctrv.2017.11.009_b0320","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00228-015-1874-3","article-title":"Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: a prospective female cohort study on >2000 ECGs","volume":"71","author":"Diemberger","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ctrv.2017.11.009_b0325","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40261-016-0460-5","article-title":"Targeted cancer therapies and QT Interval prolongation: unveiling the mechanisms underlyingarrhythmic complications and the need for risk stratification strategies","volume":"37","author":"Cuni","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ctrv.2017.11.009_b0330","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/bmb\/ldp005","article-title":"The potential role and application of ParP inhibitors in cancer treatment","volume":"89","author":"Chalmers","year":"2009","journal-title":"Br Med Bull"},{"issue":"3","key":"10.1016\/j.ctrv.2017.11.009_b0335","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0340","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.2147\/OTT.S114714","article-title":"Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer","volume":"10","author":"Dockery","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"23","key":"10.1016\/j.ctrv.2017.11.009_b0345","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1158\/1078-0432.CCR-17-1337","article-title":"FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer","volume":"23","author":"Balasubramaniam","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2017.11.009_b0350","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1177\/1758834017718775","article-title":"Niraparib in ovarian cancer: results to date and clinical potential","volume":"9","author":"Caruso","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2017.11.009_b0355","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2017.11.009_b0360","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00280-016-3156-x","article-title":"Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study","volume":"78","author":"Munasinghe","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.ctrv.2017.11.009_b0365","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00280-014-2486-9","article-title":"Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors","volume":"74","author":"Plummer","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.ctrv.2017.11.009_b0370","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2017.11.009_b0375","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 Trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9737","key":"10.1016\/j.ctrv.2017.11.009_b0380","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctrv.2017.11.009_b0385","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00280-016-3124-5","article-title":"Olaparib does not cause clinically relevant QT\/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies","volume":"78","author":"Swaisland","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0390","article-title":"A Phase 1 study of single-agent ribociclib in japanese patients with advanced solid tumors","author":"Doi","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2017.11.009_b0395","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-017-4523-y","article-title":"Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial","author":"Sonke","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2017.11.009_b0400","unstructured":"Therapy Management Guide-Kisqali (Ribociclib) NOVARTIS; 2017."},{"key":"10.1016\/j.ctrv.2017.11.009_b0405","unstructured":"\u201cFDA Approves Palbociclib for Metastatic Breast Cancer\u201d. OncLive, 3 Feb 2015."},{"key":"10.1016\/j.ctrv.2017.11.009_b0410","unstructured":"\u201cPfizer Receives U.S. FDA Accelerated Approval of IBRANCE (palbociclib)\u201d. Pfizer, 3 Feb 2015."},{"issue":"5","key":"10.1016\/j.ctrv.2017.11.009_b0415","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1185\/03007995.2016.1157060","article-title":"Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment","volume":"32","author":"Bell","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.ctrv.2017.11.009_b0420","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0425","unstructured":"Data on file. Pfizer Inc, New York, NY; 2016"},{"issue":"20","key":"10.1016\/j.ctrv.2017.11.009_b0430","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2017.11.009_b0435","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ctrv.2017.11.009_b0440","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11523-017-0492-7","article-title":"Palbociclib: a review in HR-Positive, HER2-Negative, advanced or metastatic breast cancer","volume":"12","author":"Kim","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.ctrv.2017.11.009_b0445","unstructured":"Ibrance (palbociclib) European public assessment report; 2016"},{"issue":"9","key":"10.1016\/j.ctrv.2017.11.009_b0450","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1634\/theoncologist.2017-0072","article-title":"Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results","volume":"22","author":"Loibl","year":"2017","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ctrv.2017.11.009_b0455","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2017.11.009_b0460","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.3109\/10428194.2015.1030641","article-title":"Phase 1\/2 study of cyclin-dependent kinase (CDK)4\/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"56","author":"Niesvizky","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.ctrv.2017.11.009_b0465","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/bjc.2011.177","article-title":"Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2\/1)","volume":"104","author":"Schwartz","year":"2011","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2017.11.009_b0470","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2017.11.009_b0475","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000447284","article-title":"Clinical development of the CDK4\/6 inhibitors ribociclib and abemaciclib in breast cancer","volume":"11","author":"Barroso-Sousa","year":"2016","journal-title":"Breast Care (Basel)"},{"issue":"17","key":"10.1016\/j.ctrv.2017.11.009_b0480","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+\/HER2- Metastatic Breast Cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.ctrv.2017.11.009_b0485","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217302013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217302013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T12:29:50Z","timestamp":1535200190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737217302013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":98,"alternative-id":["S0305737217302013"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.009","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}